Transcript
Rahnee Jackson:
Hi, I’m Rahnee and I live in Phoenix, Arizona.
Dr. Bloomenstein:
Hi, I’m Dr. Marc Bloomenstein. I practice here in Scottsdale, Arizona.
Rahnee Jackson:
So for years I was using lubricating drops. Even after my surgery, you had me using it every couple hours throughout the day. What was it that made you want to change me over to using MIEBO?
Dr. Bloomenstein:
You know what, that’s a great question. When you and I were talking and you talked about the fluctuating vision and when you talked about the fact that, you know, towards the end of the day, it was really obvious that it was evaporative, and what’s great is that MIEBO actually directly goes to that evaporative effect.
[On-screen text]
The exact mechanism of action for MIEBO in DED is not known.
Dr. Bloomenstein:
MIEBO basically sits on the very outer layer of your cornea. It rests on the top of the tears, almost acting preventatively. And what’s nice about MIEBO is that for the vast majority of my patients, it doesn’t have a lot of discomfort.
[On-screen text]
In clinical trials, 81% of people treated with MIEBO rated it as a 7 or higher on a 0-10 comfort scale. Blurred vision and conjunctival redness were reported in 1% to 3% of patients.
Rahnee Jackson:
Yeah. What else do you feel makes MIEBO so unique?
Dr. Bloomenstein:
There’s no other medication on the market that is like MIEBO. MIEBO is water free. MIEBO is vehicle free. And that may not mean anything to you, but it basically means that the whole bottle is just the molecule perfluorohexyloctane. The other really nice thing about MIEBO is that it’s kind of a small drop.
Rahnee Jackson:
Yeah, it’s really nice.
Dr. Bloomenstein:
One of the challenges that we have when you prescribe a medication is that keeping patients adherent, keeping them on it. I mean, think about how many times you used your drops and then you just stopped using it, right? And then you come into the doctor and we’re like, girl, are you doing your drops? And you’re like, yeah, maybe. So what’s nice is when you have one that has very little side effects and it actually makes a difference. And so MIEBO is a really unique medication.
[On-screen text]
In clinical trials, the most common ocular adverse reaction was blurred vision. Blurred vision and conjunctival redness were reported in 1% to 3% of patients.
Dr. Bloomenstein:
Now that you’ve been on MIEBO, how do you think it’s affecting your evaporative dry eye symptoms?
Rahnee Jackson:
I feel so much better as far as, like, the grittiness and, you know, the focus and not really feeling the irritants anymore that I used to feel before, as far as, like, burning or just that sandpaper-like feeling. And so it’s nice because I’m still very much on my phone, binge watching, computer, working, traveling. So it’s been a great change for me over the course of this time.
[On-screen text]
At the time of this video, Rahnee was using MIEBO for ~4 months.
Dr. Bloomenstein:
Yeah. I can prescribe it for patients that want to continue their lifestyle and not really have it interrupted. Because I always kind of feel like my job is to help you to keep doing the things you want to do. And if I can reduce those symptoms, then it’s a win-win. And so it’s gratifying for me to hear that you’re able to keep doing those things.
Rahnee Jackson:
Yeah. I’m not sitting here worried about why my eyes are burning or why they’re feeling the way that they’re feeling. It’s kind of just out of sight, out of mind, and I’m able to go about my day without any added irritant.
Dr. Bloomenstein:
So that was like a pun. Out of sight. I like that.
Rahnee Jackson:
You caught on to that.
Dr. Bloomenstein:
Yeah, I did. That was cute.
I mean it’s gratifying again for me because this is a chronic condition. And it’s great to hear that MIEBO is helping you so much.
Announcer:
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information for MIEBO at MIEBO-ECP.COM.
